BCL-2 Inhibitors
May 25, 2026
BeOne Enters the BCL-2 Arena: Can BEQALZI Disrupt VENCLEXTA’s Longstanding Dominance?
Summary BeOne Medicines received accelerated approval for sonrotoclax (BEQALZI) to treat adults with relapsed or refractory mantle cell lymphoma (MCL) who have failed at least two prior therapies, including a BTK inhibitor. Backed by Phase 1/2 trial data in 103 heavily pre-treated patients, the drug distingu...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
